Treatment of Thyroid Eye Disease

被引:0
|
作者
Margaret E. Phillips
Mehrak M. Marzban
Sajeev S. Kathuria
机构
[1] University of Maryland,Department of Ophthalmology
来源
关键词
West Nile Virus; Progressive Multifocal Leukoencephalopathy; Euthyroid State; Eyelid Retraction; Orbital Inflammation;
D O I
暂无
中图分类号
学科分类号
摘要
Thyroid eye disease (TED) is an autoimmune disease characterized by varying degrees of proptosis, congestion and inflammation of the extraocular tissues, and eyelid retraction. It is usually seen in the setting of Graves’ disease, but the severity of TED does not necessarily correlate with the level of systemic disease in a given patient. It is very important, nonetheless, to try to achieve a euthyroid state to minimize the chances of exacerbation of TED. Treatment of TED is based on the signs and symptoms displayed by the patient; there is no “one size fits all” approach. Generally, it is advisable to start with conservative measures, such as ocular lubrication with artificial tears, to manage symptoms of chronic irritation and redness. It is also imperative that the patient be advised to quit smoking, because there is a clear link between smoking and disease activity. Medical treatment with systemic oral or pulsed intravenous corticosteroids should be reserved for patients with active inflammation resulting in increased orbital pressure, compressive optic neuropathy, severe periorbital edema, or similar presentations. Once there is significant improvement in the acute inflammation, it is useful to treat patients who have residual inflammation with external beam radiation in order to be able to wean the patient off steroids and avoid their well-known complications.
引用
收藏
页码:64 / 69
页数:5
相关论文
共 50 条
  • [41] The eye and thyroid disease
    Kuriyan, Ajay E.
    Phipps, Richard P.
    Feldon, Steven E.
    CURRENT OPINION IN OPHTHALMOLOGY, 2008, 19 (06) : 499 - 506
  • [42] Thyroid eye disease
    Hsu, H. -J.
    Hsu, C. -K.
    Chen, T. -S.
    Hsu, C. -H.
    QJM-AN INTERNATIONAL JOURNAL OF MEDICINE, 2016, 109 (01) : 67 - 68
  • [43] THYROID EYE DISEASE
    MUNRO, D
    BRITISH MEDICAL JOURNAL, 1993, 306 (6881): : 805 - 806
  • [44] Orbital corticosteroid injections for the treatment of active thyroid eye disease
    Eid, Kevin T.
    Kally, Peter M.
    Kahana, Alon
    FRONTIERS IN OPHTHALMOLOGY, 2024, 3
  • [45] Understanding Pathogenesis Intersects With Effective Treatment for Thyroid Eye Disease
    Smith, Terry J.
    JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2022, 107 : S13 - S26
  • [46] Teprotumumab for the treatment of thyroid eye disease: The Holy grail, really?
    Martel, A.
    JOURNAL FRANCAIS D OPHTALMOLOGIE, 2023, 46 (06): : 567 - 570
  • [47] Medical treatment of compressive optic neuropathy in thyroid eye disease
    Fouladi, MK
    Burnett, CAM
    Potts, MJ
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 1999, 40 (04) : S25 - S25
  • [48] Proptosis Regression After Teprotumumab Treatment for Thyroid Eye Disease
    Rosenblatt, Tatiana R.
    Chiou, Carolina A.
    Yoon, Michael K.
    Wolkow, Natalie
    Lee, Nahyoung Grace
    Freitag, Suzanne K.
    OPHTHALMIC PLASTIC AND RECONSTRUCTIVE SURGERY, 2024, 40 (02): : 187 - 191
  • [49] Perspective on the Current Role of Teprotumumab in Treatment of Thyroid Eye Disease
    Allen, Richard C.
    Bradley, Elizabeth A.
    Fante, Robert G.
    Lucarelli, Mark J.
    OPHTHALMOLOGY, 2021, 128 (08) : 1125 - 1128
  • [50] Reactivation After Teprotumumab Treatment for Active Thyroid Eye Disease
    Hwang, Catherine J.
    Rebollo, Nicole P.
    Mechels, Keegan B.
    Perry, Julian D.
    AMERICAN JOURNAL OF OPHTHALMOLOGY, 2024, 263 : 152 - 159